文献速递心脏核医学

心脏PET显像在心脏淀粉样变性中的作用

The role of cardiac PET imaging in cardiac amyloidosis.
PubMed 文献 · Semin Nucl Med · 2026-05-31

本文综述心脏PET显像在心脏淀粉样变性中的病理生理原理、现有与新兴示踪剂、临床应用、诊断效能及未来方向。淀粉样蛋白特异性PET示踪剂如11C-PiB、18F-florbetapir、18F-florbetaben及新型泛淀粉样示踪剂124I-evuzamitide能高灵敏度检测ATTR和AL型心脏淀粉样变性并定量淀粉样负荷。PET有望用于早期检测、评估常规影像不确定发现、全身评估及纵向监测治疗反应。

要点

  • 淀粉样蛋白特异性PET示踪剂可高灵敏度检测ATTR和AL型心脏淀粉样变性。
  • PET可定量评估淀粉样负荷并有望纵向监测治疗反应。
  • PET可用于评估常规影像不确定发现及全身系统性淀粉样变性。

核心结论

  • 心脏PET显像有望成为系统性淀粉样疾病精准医学的重要组成部分。

研究设计与样本

  • 本文为综述,总结心脏PET显像在心脏淀粉样变性中的病理生理原理、现有与新兴示踪剂、临床应用、诊断效能及未来方向。

主要发现

  • 淀粉样蛋白特异性PET示踪剂如11C-PiB、18F-florbetapir、18F-florbetaben及新型泛淀粉样示踪剂124I-evuzamitide能高灵敏度检测ATTR和AL型心脏淀粉样变性并定量淀粉样负荷。
  • 新兴证据提示PET显像可能有助于更早发现疾病、改善对常规影像不确定发现的评估、提供系统性淀粉样变性的全身评估,并在疾病修饰治疗时代纵向监测治疗反应。

临床怎么用

  • 心脏PET显像可用于检测ATTR和AL型心脏淀粉样变性并定量淀粉样负荷。
  • PET显像可能用于评估常规影像不确定发现及全身系统性淀粉样变性。
  • PET显像可能用于纵向监测心脏淀粉样变性的治疗反应。

局限性

  • 当前心脏PET显像在成本、可获得性、标准化和监管批准方面存在局限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Cardiac amyloidosis is an increasingly recognized infiltrative cardiomyopathy characterized by extracellular deposition of misfolded amyloid fibrils within the myocardium, leading to progressive heart failure, arrhythmias, and increased mortality. Although technetium-99m (Tc-99m) bone scintigraphy revolutionized the noninvasive diagnosis of transthyretin (ATTR) cardiac amyloidosis, important limitations remain, including limited quantification, reduced utility in immunoglobulin light-chain (AL) amyloidosis, and inability to comprehensively assess systemic disease burden or therapeutic response. Positron emission tomography (PET) has emerged as a promising next-generation molecular imaging modality capable of directly targeting amyloid fibrils and associated extracellular components. This review summarizes the evolving role of cardiac PET imaging in cardiac amyloidosis, including pathophysiologic principles, currently available and emerging radiotracers, clinical applications, diagnostic performance, and future directions. Amyloid-specific PET tracers such as 11C-PiB, 18F-florbetapir, 18F-florbetaben, and the novel pan-amyloid tracer 124I-evuzamitide demonstrate the ability to detect both ATTR and AL cardiac amyloidosis with high sensitivity while enabling quantitative assessment of amyloid burden. Emerging evidence suggests PET imaging may facilitate earlier disease detection, improve evaluation of equivocal conventional imaging findings, provide whole-body assessment of systemic amyloidosis, and allow longitudinal monitoring of treatment response in the era of disease-modifying therapies. Despite current limitations related to cost, availability, standardization, and regulatory approval, cardiac PET imaging is poised to become an increasingly important component of precision medicine approaches for systemic amyloid diseases. Continued advances in tracer development, quantitative imaging, and hybrid molecular imaging techniques are likely to further expand the role of PET in diagnosis, risk stratification, and therapeutic monitoring of cardiac amyloidosis.

来源:Semin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Al-Mallah MH. The role of cardiac PET imaging in cardiac amyloidosis. Semin Nucl Med. 2026. PMID: 42218056. doi:10.1053/j.semnuclmed.2026.05.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。